End-Stage Renal Disease Treatment Choices Model brings greater access to home dialysis for patients with kidney failure
DEERFIELD, Ill. - September 18, 2020
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today issued this statement:
We are pleased that the End-Stage Renal Disease (ESRD) Treatment Choices (ETC) payment model, a core component of the Administration's Advancing American Kidney Health Initiative (AAKHI), has been finalized. We believe patients with kidney failure deserve greater access to home dialysis so they can make the best treatment choice for themselves and their families. Baxter applauds this groundbreaking effort and remains committed to working closely with healthcare providers to increase home dialysis adoption.